Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluoxetine: activating and sedating effects

C M Beasley1, J H Potvin

  • 1Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285.

International Clinical Psychopharmacology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy.

Journal of clinical psychopharmacology·2002
Same author

A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.

International journal of geriatric psychiatry·2001
Same author

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

The Journal of clinical psychiatry·2001
Same author

Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.

The Journal of clinical psychiatry·2001
Same author

Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.

Clinical therapeutics·2000
Same author

Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.

The Journal of clinical psychiatry·2000
Same journal

Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.

International clinical psychopharmacology·2026
Same journal

Expanding the horizon of brexpiprazole augmentation in treatment-resistant disorders: from obsessive-compulsive disorder to adolescent bipolar disorder.

International clinical psychopharmacology·2026
Same journal

Acceptability-adjusted speed in psychotic agitation: interpreting pro re nata antipsychotic data in real-world care (commentary on Hatta et al.).

International clinical psychopharmacology·2026
Same journal

Antipsychotics in clinical practice: agitation, polypharmacy, and treatment resistance.

International clinical psychopharmacology·2026
Same journal

Methylphenidate treatment in adults with comorbid attention-deficit/hyperactivity disorder and borderline personality disorder: a prospective longitudinal study.

International clinical psychopharmacology·2026
Same journal

Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026
See all related articles

Fluoxetine, a serotonin uptake inhibitor, can cause both activating and sedating side effects in patients with major depressive disorder. Activation rates increased at higher doses, while sedation increased linearly with dose, with both phenomena differing in temporal patterns.

Area of Science:

  • Psychiatry
  • Clinical Pharmacology
  • Neuroscience

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for major depressive disorder.
  • SSRIs are often associated with activating or sedating side effects.
  • Understanding dose-effect relationships of these side effects is crucial for treatment optimization.

Purpose of the Study:

  • To evaluate the rates, temporal patterns, and dose-effect relationships of activation and sedation associated with fluoxetine treatment.
  • To compare these effects across different fixed doses of fluoxetine in patients with major depressive disorder.

Main Methods:

  • Analysis of adverse event data from two fixed-dose studies of fluoxetine (5-60 mg/day) versus placebo in major depressive disorder.
  • Categorization of adverse events into 'activation' (nervousness, anxiety, agitation, insomnia) and 'sedation' (somnolence, asthenia).

Related Experiment Videos

Main Results:

  • Both activation and sedation were statistically significant treatment-emergent phenomena.
  • Activation rates were stable from 5-40 mg/day, increasing at 60 mg/day.
  • Sedation rates increased linearly up to 40 mg/day, plateauing at 60 mg/day.
  • Discontinuations due to these side effects were infrequent.
  • Activation peaked early and declined; sedation also peaked early but showed potentially greater variability and slower decline.

Conclusions:

  • Fluoxetine exhibits distinct dose-effect relationships for activation and sedation in major depressive disorder.
  • Activation and sedation present different temporal patterns of onset and persistence.
  • These findings aid in managing SSRI-induced side effects and optimizing fluoxetine dosing strategies.